Login to Your Account

Deal removes uncertainty

Roivant in 'left-field' entry to diabetes with $650M pact on Poxel's imeglimin

By Cormac Sheridan
Staff Writer

Tuesday, February 13, 2018

DUBLIN – Shares in Poxel SA rose as much as 32 percent Monday on the back of a partnering deal with Roivant Sciences GmbH, in which it is getting $35 million up front, $15 million in equity investment and potentially $600 million in development, regulatory and commercialization milestones for ex-Asia rights to its oral type 2 diabetes drug imeglimin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription